{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:24:57Z","timestamp":1791465897433,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":889,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1093\/annonc\/mdx192","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T05:21:13Z","timestamp":1493702473000},"page":"1949-1956","source":"Crossref","is-referenced-by-count":166,"title":["ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia"],"prefix":"10.1016","volume":"28","author":[{"given":"D.","family":"Currow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Temel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Milanowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Friend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx192_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdx192_bb0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13539-014-0164-8","article-title":"Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014","volume":"5","author":"Von Haeling","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1093\/annonc\/mdx192_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdx192_bb0025","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00520-014-2534-3","article-title":"Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer","volume":"23","author":"Kimura","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdx192_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1188\/10.CJON.72-80","article-title":"An interdisciplinary approach to manage cancer cachexia","volume":"14","author":"Granda-Cameron","year":"2010","journal-title":"Clin J Oncol Nurs"},{"issue":"electronic Suppl 1","key":"10.1093\/annonc\/mdx192_bb0035","doi-asserted-by":"crossref","first-page":"eS51","DOI":"10.3949\/ccjm.79.s2.11","article-title":"The emerging role of palliative medicine in the treatment of lung cancer patients","volume":"79","author":"Davis","year":"2012","journal-title":"Cleve Clin J Med"},{"issue":"6","key":"10.1093\/annonc\/mdx192_bb0040","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00520-012-1697-z","article-title":"Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients","volume":"21","author":"Wallengren","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/B978-0-12-410473-0.00003-9","article-title":"The role of ghrelin in anorexia-cachexia syndromes","volume":"92","author":"Guillory","year":"2013","journal-title":"Vitam Horm"},{"issue":"8","key":"10.1093\/annonc\/mdx192_bb0050","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/cncr.24917","article-title":"Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study","volume":"116","author":"Lundholm","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0055","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1002\/cncr.27430","article-title":"Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study","volume":"118","author":"Hiura","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0060","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/sj.bjc.6604148","article-title":"Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia\/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study","volume":"98","author":"Strasser","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0065","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdx192_bb0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00520-012-1500-1","article-title":"Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study","volume":"21","author":"Garcia","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0075","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdx192_bb0080","first-page":"S269","article-title":"Efficacy and safety of anamorelin HCl in NSCLC patients: results from a randomized, double-blind, placebo-controlled, multicentre phase II study","volume":"49","author":"Temel","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx192_bb0090","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1023\/A:1016670403148","article-title":"Re-validation and shortening of the Functional Assessment of Anorexia\/Cachexia Therapy (FAACT) questionnaire","volume":"9","author":"Ribaudo","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdx192_bb0095","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1530\/EJE-14-0183","article-title":"Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions","volume":"171","author":"Heppner","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1093\/annonc\/mdx192_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","article-title":"The role of insulin resistance in the development of muscle wasting during cancer cachexia","volume":"3","author":"Honors","year":"2012","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1093\/annonc\/mdx192_bb0105","first-page":"320","article-title":"MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism","volume":"83","author":"Murphy","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1093\/annonc\/mdx192_bb0110","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1210\/jc.2007-2018","article-title":"Acute effects of ghrelin administration on glucose and lipid metabolism","volume":"93","author":"Vestergaard","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1093\/annonc\/mdx192_bb0115","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpdd.175","article-title":"An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin","volume":"4","author":"Leese","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1093\/annonc\/mdx192_bb0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.critrevonc.2013.07.015","article-title":"Clinical evaluation and optimal management of cancer cachexia","volume":"88","author":"Tuca","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdx192_bb0125","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ejca.2008.02.033","article-title":"Cancer cachexia: developing multimodal therapy for a multidimensional problem","volume":"44","author":"Fearon","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdx192_bb0130","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.jpainsymman.2012.06.013","article-title":"Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report","volume":"45","author":"Rhondali","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1093\/annonc\/mdx192_bb0135","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1634\/theoncologist.9-5-556","article-title":"Non-small cell lung cancer in the elderly","volume":"9","author":"Makrantonakis","year":"2004","journal-title":"Oncologist"},{"issue":"4","key":"10.1093\/annonc\/mdx192_bb0140","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1758834010366707","article-title":"Treating advanced non-small cell lung cancer in the elderly","volume":"2","author":"Maione","year":"2010","journal-title":"Ther Adv Med Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419321398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/8\/1949\/24169554\/mdx192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:21:59Z","timestamp":1624681319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419321398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0923753419321398"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx192","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}